Multiple approved glucagon-like peptide 1 (GLP1) and gastric inhibitory polypeptide (GIP) agonists [12] (alone or in combinations) induce highly significant weight loss in persons with obesity [13]. Here, GIP is linked to obesity due to melanocortin 4 receptor deficiency.